<DOC>
	<DOCNO>NCT02871167</DOCNO>
	<brief_summary>The aim study perform French multicenter prospective interventional study order ass feasibility safety ovarian hyperstimulation oocyte / embryo cryopreservation young woman breast cancer . The oncologic reproductive benefit / risk ratio investigate oncology reproductive area .</brief_summary>
	<brief_title>Risk Infertility Related Adjuvant Chemotherapy Early Breast Cancer : Oocyte/Embryo Cryopreservation</brief_title>
	<detailed_description>Medical Oncology : - Information collection consent , - Imaging staging , - Inclusion - Physical examination - Contraception advise give Reproductive medicine center : - Ovarian reserve assessment : serum anti-mullerian hormone ( AMH ) measurement antral follicle count ( AFC ) ultrasound . - Serology syphilis , hepatitis B C , HIV ( human immunodeficiency virus ) . In case embryo cryopreservation , serology determination men . - Infertility risk fertility preservation technique information . - In case agreement , technique do time-interval surgery chemotherapy - Fertility preservation ( COH stimulation , trigger oocyte retrieval ) Adjuvant chemotherapy : - The chemotherapy regimen 3 FEC ( fluorouracil epirubicin cyclophosphamide ) 100 follow 3 Docetaxel +/- Trastuzumab . Adjuvant chemotherapy may begin oocyte retrieval . - Usual adjuvant chemotherapy change During chemotherapy : - Clinical exam cycle chemotherapy - AMH , AFC cycle 6 After chemotherapy : - Usual patient monitoring expert center : physical examination Month 3 ( M3 ) , M6 M9 M12 M18 M24 mammography M9 annual - AMH Month 3 ( M3 ) , M6 M9 M12 M18 M24 - AFC Month 12 ( M12 ) M24</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<criteria>Women histologically proven breast cancer Aged 18 38 year old Planned adjuvant chemotherapy No prior chemotherapy Affiliated public health insurance program Informed consent sign patient Metastatic breast cancer Planned neoadjuvant chemotherapy Hysterectomy Exclusive adjuvant hormonotherapy Positive serology syphilis , hepatitis B C , VIH Contraindication relate use rFSH Pregnant breastfeeding patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>oocyte/embryo cryopreservation</keyword>
</DOC>